Adiponectin and prognostic outcome in patients with coronary artery disease: reply
Open Access
- 13 May 2008
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 29 (20) , 2579-2580
Abstract
The letter by Cesari et al.1 refers to yet unpublished data on the association between plasma adiponectin and prognostic outcome in patients with coronary heart disease (CHD). The authors exclusively focused on total adiponectin levels and did not consider its multimeric isoforms, such as the high-molecular weight isoform. In accordance with our study,2 adiponectin levels did not yield additional predictive value for secondary cardiovascular disease events in addition to traditional cardiovascular risk factors after appropriate adjustment for covariates and consequently may not be regarded as an independent biomarker for future risk in patients with prevalent CHD. However, we like to emphasize distinct differences regarding patient selection and design of the two studies resulting in important consequences for data interpretation.Keywords
This publication has 5 references indexed in Scilit:
- Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart diseaseEuropean Heart Journal, 2007
- Relationship of Adiponectin with Markers of Systemic Inflammation, Atherogenic Dyslipidemia, and Heart Failure in Patients with Coronary Heart DiseaseClinical Chemistry, 2006
- Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart FailureCirculation, 2005
- Adiponectin and Future Coronary Heart Disease Events Among Men With Type 2 DiabetesDiabetes, 2005
- Plasma Adiponectin Levels and Risk of Myocardial Infarction in MenJAMA, 2004